Efficacy of a nutraceutical combination therapy for improving symptoms and quality of life in chronic venous disease

BACKGROUND: To evaluate the effectiveness of a nutraceutical combination therapy (Flebo Up®) on relieving symptoms and signs of chronic venous disease (CVD), compared with a group of patients treated with a reference drug (Daflon®).METHODS: Data of patients affected by CVD class C0-C4 according to the CEAP classification who took either Daflon® 500 mg twice a day or Flebo Up® 500 mg daily for at least 3 months were analyzed. A P value <0.05 was considered statistically significant.RESULTS: Data of 160 patients (80 each group) were analyzed. After 1 month, patients treated with Flebo Up® experienced a significant reduction of leg pain (64.7%), of heaviness (59.6%), of nocturnal cramps 65.1% and of leg circumference, if compared to the enrollment status and also to the group of patients treated with Daflon® (P<0.001).CONCLUSIONS: After one month, Flebo Up® induced a significant reduction of leg pain, heaviness, nocturnal cramps and leg circumference, acting more rapidly than Daflon®.